Recent 8-K filings for ALLO

• June 22, 2026, 4:05 PM ET other material materiality 0.70 neutral item 5.07item 8.01item 9.01 ◈ Shareholder Votes ×5

  Allogene shareholders approve doubling authorized shares to 800M; files $135M ATM offering

  Stockholders approved increase of authorized common shares from 400M to 800M, effective June 18, 2026.

• May 28, 2026, 5:06 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change ×5

  Allogene appoints Zachary Roberts as CEO effective July 1, 2026; David Chang becomes non-employee director

  Zachary Roberts, M.D., Ph.D., currently EVP R&D and CMO, named President and CEO effective July 1, 2026.

• May 13, 2026, 4:03 PM ET earnings materiality 0.65 neutral item 1.01item 1.02item 2.02item 9.01 ◈ Material Agreements ×2◈ Earnings Releases

  Allogene Q1 net loss $42.6M; ALPHA3 interim shows 58% MRD clearance; cash runway extended to Q1 2029

  Terminated exclusive license with Overland; retains ~3% equity; no termination payments.

• April 15, 2026, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Allogene prices $175M public offering of 87.5M shares at $2.00 per share

  Offering of 87,500,000 shares at $2.00/share; gross proceeds ~$175M before discounts and expenses.

• April 13, 2026, 7:59 PM ET other material materiality 0.80 positive item 8.01

  Allogene's cema-cel shows 41.6% MRD clearance advantage in ALPHA3 Phase 2 interim

  58.3% (7/12) of cema-cel patients achieved MRD negativity vs 16.7% (2/12) in observation arm.

• April 13, 2026, 7:59 PM ET other material materiality 0.65 negative item 8.01

  Allogene Therapeutics launches underwritten public offering, suspends ATM sales

  Company announced proposed underwritten public offering of common stock on April 13, 2026.

• March 12, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Allogene Q4 net loss $38.8M; cash runway into Q1 2028; cema-cel ALPHA3 interim April 2026

  Q4 net loss $38.8M ($0.17/share); FY 2025 net loss $190.9M ($0.87/share).

• November 6, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Allogene Therapeutics Reports Q3 2025 Net Loss of $41.4M, Cash of $277.1M

  Q3 2025 net loss $41.4M ($0.19 per share), cash $277.1M, cash runway into 2H 2027.

• October 14, 2025, 7:59 PM ET litigation materiality 0.65 negative item 8.01

  Allogene reports patent infringement lawsuit against licensor Cellectis by Factor Bioscience

  Factor Bioscience filed a complaint in Delaware against Cellectis and AstraZeneca on Sept 26, 2025, alleging TALEN gene-editing patent infringement.

• August 13, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Allogene Q2 net loss $50.9M; highlights ALPHA3 trial progress and ALLO-329 autoimmune initiation

  Net loss of $50.9M ($0.23/share) for Q2 2025; cash and investments $302.6M as of June 30, 2025.

• August 1, 2025, 7:59 PM ET other material materiality 0.90 negative item 8.01

  Allogene drops ALLO-647 after Grade 5 death; pivots to Dagger platform

  Grade 5 hepatic failure from adenovirus attributed to ALLO-647; FC+ALLO-647 arm closed in ALPHA3 study.

• June 23, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07item 9.01

  Allogene shareholders elect three Class I directors, approve say-on-pay, ratify auditor

  Elizabeth Barrett, Arie Belldegrun, and David Chang elected as Class I directors with >131M votes for each.

• May 13, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Allogene Q1 net loss $59.7M; ALPHA3 milestone delayed to 1H 2026; cash runway to 2H 2027

  Net loss $59.7M ($0.28/sh); R&D $50.2M, G&A $15M; cash, equivalents & investments $335.5M.

• March 13, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Allogene reports Q4 net loss $59.9M; cash $373.1M; pipeline milestones 2025-2027

  Q4 net loss $59.9M ($0.28/share); FY net loss $257.6M ($1.32/share); R&D expense $45M Q4.

• February 25, 2025, 6:59 PM ET other material materiality 0.55 neutral item 1.01

  Allogene expands collaboration with Foresight for MRD companion diagnostic; commits $37.3M

  Amended agreement covers MRD assay development as companion diagnostic for cema-cel in EU, UK, Canada, Australia.

• January 29, 2025, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 ◈ executive_change

  Allogene Therapeutics officer Timothy Moore to depart Feb 28, 2025

  Timothy Moore leaving employment on February 28, 2025; departure treated as termination without cause.

• November 13, 2024, 6:59 PM ET other material materiality 0.60 negative item 8.01

  Allogene discontinues enrollment in Phase 1 cema-cel CLL trial due to slow accrual

  Discontinued the Phase 1 cohort in ALPHA2 trial for cema-cel in relapsed/refractory CLL after BTKi/BCL2i therapy.

• November 7, 2024, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Allogene Q3 2024 net loss $66.3M; cash $403.4M; cash runway into 2H 2026

  Net loss of $66.3M ($0.32/share) including $13.4M stock-based comp and $10.7M impairment; R&D $44.7M, G&A $16.3M.

• October 7, 2024, 7:59 PM ET other materiality 0.05 neutral item 5.05item 9.01 ◈ Governance Changes

  Allogene Therapeutics amends Code of Business Conduct and Ethics

  Updates insider trading policy, antitrust restrictions, and conflicts-of-interest procedures.

• August 7, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Allogene Q2 net loss $66.4M ($0.35/sh); initiated pivotal ALPHA3 trial for cema-cel

  Net loss of $66.4M ($0.35 per share) includes $13.6M stock-based comp and $5.0M impairment.

• June 10, 2024, 7:59 PM ET leadership materiality 0.25 neutral item 5.02item 5.07item 9.01 ◈ executive_change ×2

  Allogene appoints new principal accounting officer; shareholders elect directors and ratify auditor

  Annie Yoshiyama appointed principal accounting officer, replacing Geoffrey Parker; Parker remains CFO.

• May 31, 2024, 7:59 PM ET M&A materiality 0.65 neutral item 1.01

  Allogene restructures JV; ownership diluted to 15.4%, license royalty amended to flat mid-single-digit

  JV acquires Overland US (lead asset OL-101, autologous GPRC5D-BCMA CAR-T for multiple myeloma).

• May 14, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Allogene Therapeutics raises $110M in registered equity offering at $2.90 per share with insider participation

  Offering of 37,931,035 shares at $2.90 per share for gross proceeds of ~$110M; expected to close May 16, 2024.

• May 13, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Allogene expands CD19 rights to EU/UK; Q1 net loss $65M; cash $397M into 2026

  Expanded CD19 oncology rights to all EU Member States and UK from Servier; combined market opportunity increased to >$9.5B from $6B.

• March 14, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Allogene reports Q4 net loss $85.8M, cash $448.7M; ALPHA3 trial to start mid-2024

  Net loss Q4 2023 $85.8M ($0.51/share); full-year net loss $327.3M ($2.09/share).

• February 16, 2024, 6:59 PM ET other material materiality 0.85 negative item 4.02 ◈ Auditor Changes

  Allogene restates 2020-2022 financials; material weakness in ICFR identified

  Audit Committee determined 2020-2022 annual and 2021-2023 quarterly reports should no longer be relied upon.

• January 31, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01 ◈ Material Agreements

  Allogene amends Notch collaboration, retains exclusive rights to one CAR target, gives up others

  Relinquished exclusive rights to all original CAR targets except one; option limited to one additional target.

• January 5, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 8.01item 2.05 ◈ Restructurings & Charges ×2◈ Material Agreements

  Allogene to start pivotal ALPHA3 trial in 1L LBCL; cuts 22% staff, partners with Foresight

  Workforce reduction of ~22% with estimated $5.0M-$5.5M in severance charges, mostly in Q1 2024.

• December 19, 2023, 6:59 PM ET regulatory materiality 0.75 positive item 8.01

  Allogene gets FDA Fast Track for ALLO-647; safety data from 87 patients at ASH

  FDA granted Fast Track Designation for ALLO-647 in adult patients with r/r LBCL.

• November 2, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Allogene reports Q3 net loss $61.3M; cash $497.7M; ALPHA2 on track

  Net loss of $61.3M ($0.37/sh) for Q3 2023; R&D expense $46.0M, G&A $17.0M.

• October 17, 2023, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 ◈ executive_change ×3

  Allogene appoints Geoffrey Parker as CFO with $490K salary and equity grants

  Geoffrey Parker appointed EVP, CFO, Principal Financial and Accounting Officer effective Oct 16, 2023.

• October 16, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change

  Allogene appoints Geoffrey Parker as CFO effective Oct 16, 2023

  Geoffrey Parker named EVP, CFO, Principal Financial & Accounting Officer, effective Oct 16, 2023.

• August 2, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Allogene reports Q2 2023 net loss of $78.0M; cash extends into 2H 2025

  Cash, equivalents, and investments $544.5M as of June 30, 2023; raised $87.9M via ATM in Q2.

• June 21, 2023, 7:59 PM ET other material materiality 0.65 neutral item 8.01

  Allogene reports updated Phase 1 data for ALLO-501/501A in r/r LBCL with 58% ORR and 42% CR

  In 33 CAR T-naïve patients, ORR 58%, CR 42%; 30% maintained CR at 6 months across all patients.

• June 15, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01 ◈ Shareholder Votes ×3

  Allogene Therapeutics shareholders elect four Class II directors, approve say-on-pay and auditor ratification

  Deborah Messemer, Vicki Sato, Todd Sisitsky, and Owen Witte elected as Class II directors to serve until 2026.

• June 14, 2023, 7:59 PM ET leadership materiality 0.50 negative item 5.02 ◈ executive_change

  CFO Eric Schmidt resigns effective August 2, 2023; search underway

  Eric Schmidt, Ph.D., CFO, principal financial and accounting officer, resigned effective August 2, 2023.

• June 7, 2023, 7:59 PM ET other material materiality 0.75 positive item 8.01

  Allogene reports 67% ORR and 58% CR in Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in r/r LBCL

  67% ORR and 58% CR in CAR T-naive r/r LBCL patients (n=12) treated with Phase 2 regimen at ASCO.

• May 3, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Allogene reports Q1 net loss $98.7M, cash $514M; clinical progress in ALLO-501A and ALLO-316

  Net loss $98.7M ($0.68/share); R&D $80.2M, G&A $18.9M; cash $514M as of March 31, 2023.

• April 20, 2023, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change ×2

  Allogene CTO Alison Moore resigns; Tim Moore appointed as replacement

  Alison Moore resigns as Chief Technical Officer effective April 28, 2023 to pursue other opportunities.

• March 10, 2023, 6:59 PM ET other material materiality 0.70 positive item 7.01

  Allogene Therapeutics has no cash deposits or securities at Silicon Valley Bank

  Company confirms zero exposure to SVB amid its closure and industry uncertainty.

• February 28, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Allogene reports Q4 2022 net loss $94.8M, cash $576.5M; pipeline advances

  Net loss Q4 2022 $94.8M ($0.66/share); full year net loss $332.6M ($2.32/share).

• January 3, 2023, 6:59 PM ET leadership materiality 0.65 negative item 5.02 ◈ executive_change

  Allogene Therapeutics EVP of R&D Rafael Amado resigns effective Dec 30, 2022

  Rafael G. Amado, Executive Vice President of Research and Development, resigned.

• November 29, 2022, 6:59 PM ET other material materiality 0.70 neutral item 8.01

  Allogene releases Phase 1 data across CAR T programs; initiates Phase 2 ALPHA2 trial

  Single Dose FCA90 in LBCL achieved 67% ORR, 58% CR; 50% in CR at 6 and 12 months. No Grade 3+ CRS or neurotoxicity.

• November 2, 2022, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Allogene reports Q3 net loss of $83.1M; initiates first allogeneic CAR T Phase 2 trial

  Net loss $83.1M ($0.58/share); R&D expenses $63.6M; G&A $18.9M.

• October 6, 2022, 7:59 PM ET other material materiality 0.60 neutral item 8.01

  Allogene initiates Phase 2 ALPHA2 trial of ALLO-501A in r/r LBCL; plans EXPAND trial for ALLO-647

  ALPHA2 trial will enroll ~100 r/r LBCL patients with single 120M CAR+ cell dose; primary endpoint ORR.

• September 21, 2022, 7:59 PM ET other material materiality 0.80 negative item 8.01

  Servier discontinues CD19 development; Allogene may exercise ex-US license at added cost

  Servier sent discontinuation notice for CD19 products (UCART19, ALLO-501, ALLO-501A) per Servier Agreement.

• August 9, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Allogene expects FDA clearance for first allogeneic CAR T pivotal trial; Q2 net loss $74.8M

  FDA clearance expected in coming weeks for Phase 2 pivotal trial of ALLO-501A in LBCL; would be first allogeneic CAR T pivotal trial.

• July 12, 2022, 7:59 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

  Allogene appoints Stephen Mayo, Ph.D. to Board; board expands to 12

  Board increased from 11 to 12; Mayo appointed as Class III director, term expires at 2024 annual meeting.

• June 17, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07item 9.01

  Allogene shareholders elect directors, approve authorized share increase to 400M

  Four Class I directors elected: Elizabeth Barrett, Arie Belldegrun, David Bonderman, David Chang.

• May 4, 2022, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Allogene reports Q1 net loss $79.9M, cash $733M; plans pivotal ALLO-501A trial mid-2022

  Net loss $79.9M ($0.56/sh); R&D $60.2M, G&A $19.9M; cash $733.1M at March 31, 2022.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

7 positive 8 negative 35 neutral

source · ALLO on sec.gov